Pearl Steinzor

Current cigarette and electronic nicotine delivery systems (ENDS) were associated with elevated wheezing, but not ENDS use alone, according to a new study.

Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, discusses the use of systemic therapies vs biologics and why adherence is so important when treating patients with atopic dermatitis (AD).

Larry Eichenfield, MD, professor of dermatology and pediatrics and vice chair of the Department of Dermatology at the University of California San Diego School of Medicine and chief of pediatric and adolescent dermatology at Rady Children's Hospital San Diego, discusses the use of different treatments and biologics for atopic dermatitis (AD) in infants, which he presented at the Revolutionizing Atopic Dermatitis conference.

A positive association between asthma and overall cancer risk was found, according to this new study.

Melinda Gooderham, MSc, MD, FRCPC, dermatologist and clinical researcher at Peterborough Regional Health Centre, discusses emerging topical and biologic therapies expected to be available later this year.

Robert Sidbury, MD, MPH, professor of pediatrics at Seattle Children's Hospital, discusses treatment approaches for atopic dermatitis of the face in infancy, which he presented at the Revolutionizing Atopic Dermatitis conference.

On this episode of Managed Care Cast, we speak with Bruce W. Sherman, MD, of Case Western Reserve University School of Medicine, about a recent study on wage-level disparities affecting the utilization of mental health resources, for which he was lead investigator; the study article appears in the April issue of The American Journal of Managed Care®.

The study examined the prevalence of prescription medications in jails and state prisons for individuals with chronic conditions, such as asthma, type 2 diabetes, hypertension, hepatitis B and C, HIV infection, depression, and severe mental illness, compared with the general population.

Jonathan Silverberg, MD, PhD, MPH, professor of dermatology and director of clinical research and patch testing at the George Washington University School of Medicine and Health Sciences, and chair of the Revolutionizing Atopic Dermatitis (RAD) conference, discusses some of the symposia and events at this year's conference that he is looking forward to the most.

Improved survival rates suggest long-term noninvasive therapy (LTH-NIV) may benefit patients with acute hypercapnic exacerbations of chronic obstructive pulmonary disorder (AECOPD).

For patients with aspirin-exacerbated respiratory disease (AERD), omalizumab significantly reduced their symptoms, according to one study.

Individuals with severe type 2 asthma and chronic rhinosinusitis with nasal polyps may benefit from the biologic treatment, dupilumab.

Judy Alberto, MHA, RPh, BCOP, director of clinical initiatives at the Community Oncology Alliance, discusses the importance of making sure oncology practices are educated about their value-based enterprise exception when mailing patients their cancer medications.

Debra Patt, MD, PhD, MBA, executive vice president at Texas Oncology, explains the small potential risk of breast cancer associated with hormonal birth control.

Shiela Plasencia, director of practice support at the Community Oncology Alliance, discusses the benefits of collecting social determinants of health data for both the patient and provider.

Sleep and genetics play individual roles in increasing a person’s risk for asthma, but their combination also heightens that risk.

Physicians may be able to better identify patients with chronic cough using the combination of 2 coughing tests.

Amy Valley, vice president for clinical strategy and technology solutions at Cardinal Health, weighs both the benefits and potential risks of physicians using artificial intelligence technology in their oncology practices.

Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, discusses the use of biosimilars and how pharmacy benefit managers (PBMs) as well as payers have challenged the biosimilar market.

People with chronic obstructive pulmonary disease (COPD) are at increased risk of long-term hearing loss, researchers find.

Debra Patt, MD, PhD, MBA, executive vice president at Texas Oncology, discusses her recent testimony to the US Senate on a case in which prior authorization caused a 6-week wait for a consult.

Nicolas Ferreyros, managing director at Community Oncology Alliance (COA), discusses the recent Senate commerce hearing on pharmacy benefit managers (PBMs), which brought bipartisan attention and energy towards addressing the concerns related to PBMs in Washington.

Researchers compared the effectiveness of 3 biologics for moderate to severe asthma in an observational study and found superior improvement with dupilumab.

Children born preterm are more likely to have respiratory symptoms at least up to middle age, according to one study.

Using gene enrichment analysis, a genome-wide association study (GWAS) identified a strong association with chronic obstructive pulmonary disease (COPD) and multiple ancestry groups.

Mike Lattanzi, MD, genitourinary medical oncologist, Texas Oncology, discusses the importance of keeping pace with precision oncology options as rates for prostate cancer increase.

The Assessment of Burden Chronic Conditions (ABCC) tool adds validity when measuring burden of disease among people with chronic conditions, according to one study.

A study including data from more than 2 million patients highlights gender, health insurance, and income disparities in patients receiving extracorporeal membrane oxygenation (ECMO) while hospitalized for severe respiratory illness.

Rates of asthma diagnoses declined at the beginning at the pandemic compared with rates of new diagnoses in the previous 3 years, according to one study.

Biomarker testing is a key tool in lung cancer treatment, and Kentucky recently passed a law requiring payers to cover biomarker tests with the intention to address high rates of lung cancer in the state.